ERBB2 and breast cancer: During the time period when the ESTHER study recruited multiple lines of treatment were available for the treatment of HER2-positive advanced breast cancer, yet it is clear from the data presented that many patients die before being able to receive another line of treatment, with a maximum of 76.8% receiving 2nd line treatment and 47.6% receiving third line treatment.